| Title |
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
|
|---|---|
| Published in |
Multiple Sclerosis and Related Disorders, January 2022
|
| DOI | 10.1016/j.msard.2021.103448 |
| Pubmed ID | |
| Authors |
David Baker, Amy MacDougall, Angray S. Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson |
Twitter Demographics
The data shown below were collected from the profiles of 22 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 8 | 36% |
| United States | 5 | 23% |
| Israel | 1 | 5% |
| France | 1 | 5% |
| Belgium | 1 | 5% |
| Unknown | 6 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 73% |
| Scientists | 3 | 14% |
| Practitioners (doctors, other healthcare professionals) | 3 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 48 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 13% |
| Student > Bachelor | 5 | 10% |
| Other | 4 | 8% |
| Student > Doctoral Student | 4 | 8% |
| Unspecified | 4 | 8% |
| Other | 6 | 13% |
| Unknown | 19 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 17% |
| Unspecified | 5 | 10% |
| Neuroscience | 4 | 8% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Agricultural and Biological Sciences | 3 | 6% |
| Other | 9 | 19% |
| Unknown | 16 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2022.
All research outputs
#1,303,777
of 24,336,902 outputs
Outputs from Multiple Sclerosis and Related Disorders
#90
of 2,944 outputs
Outputs of similar age
#32,415
of 509,166 outputs
Outputs of similar age from Multiple Sclerosis and Related Disorders
#5
of 150 outputs
Altmetric has tracked 24,336,902 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,944 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 509,166 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 150 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.